Modern Medicine: AI and Patents

Modern medicine begins not with a pill, but with a molecule.

Imagine sculptors at the atomic scale, forging molecules that precisely latch onto biological targets. This is modern structure-based drug design. Scientists are now designing drugs at the molecular level, using powerful computational tools to engineer molecules that bind precisely to disease-related proteins.

This method, known as structure-based drug design, relies on high-resolution images of proteins obtained through techniques like X-ray crystallography or cryo-electron microscopy. Once researchers identify a "binding pocket" on the target protein, they use software to simulate how different chemical structures might interact with it. This digital modeling-called molecular docking-helps predict which compounds are most likely to work, long before any lab tests can begin.

One especially cutting-edge approach is de-novo (from scratch) drug design. Rather than modifying existing drugs, researchers use algorithm-driven programs to build entirely new molecules from scratch. These algorithms, often based on artificial intelligence, craft structures that are chemically stable, biologically active, and tailored to fit specific molecular targets. This in silico (computer-based) process accelerates early-stage discovery and significantly reduces the cost of identifying promising candidates.

But no matter how elegant the design, a drug still must survive the long march of testing: lab research, animal studies, and three phases of human trials. This development path often takes 10 to 15 years and costs upwards of 1 billion dollars.

To protect that investment, companies rely on patents- legal monopolies that last 20 years from the date of filing. In theory, patents incentivize innovation. In practice, they also raise complex questions about access and affordability.

Many pharmaceutical companies engage in a tactic called ‘evergreening’ where they file multiple secondary patents on the same drug-covering everything from manufacturing tweaks to packaging design. These patent groves can extend exclusivity well beyond the original 20 years. AbbVie’s arthritis drug Humira, for example, was shielded by over 130 patents, keeping competitors off the market for nearly two decades longer than expected.

SERENA SHAH

Another common practice is "pay-for-delay," in which brand-name drug companies pay generic manufacturers to postpone launching cheaper alternatives. Though challenged in court, this strategy persists and costs consumers billions each year.

The result? Life-saving medication becomes unaffordable or inaccessible to many. In the United States, brand-name drugs account for only 10% of prescriptions but over 75% of total drug spending. Meanwhile, in lower-income countries, essential drugs remain out of reach due to restrictive patents and licensing agreements.

Pharmaceutical lobbying only complicates the picture. The industry spends more than any other on influencing policy in the U.S., with over $350 million spent annually to shape drug pricing, patent law, and regulatory standards. Reforms that could make drugs cheaper and more accessible often stall under industry pressure.

Still, change is possible. Regulatory bodies like the U.S. Federal Trade Commission (FTC) have begun cracking down on questionable patent listings. Nonprofits and global health initiatives are pushing for more equitable licensing models. And bipartisan efforts in Congress have proposed reforms to streamline generic drug approval and curb patent abuse.

In conclusion, the molecular design of a drug is a triumph of science. But whether that drug reaches the people who need it most depends on economics, law, and political will. As innovation in biotechnology accelerates, ensuring equitable access must keep pace. Because a cure that exists only on paper, or only for the wealthy, isn’t truly a cure at all.

SERENA SHAH

CITATIONS

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.

Ferreira, L. G., dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. Molecules, 20(7), 13384-13421.

Federal Trade Commission. (2010). Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions.

FTC. (2023). Statement on Challenging Improper Orange Book Patent Listings.

Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239–1249.

I-MAK. (2022). Overpatented, Overpriced: Special Report on Humira.

IQVIA Institute for Human Data Science. (2020). Medicine Use and Spending in the U.S.

Médecins Sans Frontières (MSF). (2018). Untangling the Web of Antiretroviral Price Reductions.

OpenSecrets. (2023). Pharmaceutical/Health Product Industry Profile.

Schneider, G., & Clark, D. E. (2019). Automated De Novo Drug Design: Are We Nearly There Yet? Angewandte Chemie International Edition, 58(32), 10792–10803.

U.S. Congress. (2022). REMEDY Act: Reforming Evergreening and Monopoly Extension by Drugmakers Act.